Related Experiment Videos
Crystal structure of the complex between VEGF and a receptor-blocking peptide
C Wiesmann1, H W Christinger, A G Cochran
1Department of Protein Engineering, Genentech, Inc., South San Francisco, California 94080, USA.
Biochemistry
|January 28, 1999
Summary
Researchers developed peptides targeting vascular endothelial growth factor (VEGF) to inhibit cancer growth. Structural analysis revealed a peptide that binds VEGF but is not ideal for small-molecule drug development.
Area of Science:
- Biochemistry
- Structural Biology
- Molecular Biology
Background:
- Vascular endothelial growth factor (VEGF) is a key driver of angiogenesis and a therapeutic target for cancer.
- Developing VEGF antagonists is crucial for cancer treatment strategies.
Purpose of the Study:
- To generate peptides that bind to VEGF's receptor-binding domain and inhibit receptor interaction.
- To structurally characterize a VEGF-peptide complex to guide therapeutic development.
Main Methods:
- Phage display was employed to identify peptides binding to VEGF.
- X-ray crystallography was used to determine the structure of the VEGF-peptide complex at 1.9 Å resolution.
- NMR data provided insights into peptide flexibility in solution.
Main Results:
- A 20-mer peptide was identified that binds to VEGF, forming a beta-strand interaction with VEGF's beta6 strand.
- The peptide is largely unstructured in solution but adopts an extended conformation upon binding.
- Truncation studies showed the peptide can be shortened to 14 residues with minimal affinity loss.
- The peptide-VEGF interface, while partially overlapping with the Flt-1 receptor binding site, lacks specific side-chain interactions, limiting its potential for small-molecule development.
Conclusions:
- The characterized peptide serves as a tool to understand VEGF-receptor interactions.
- The peptide's binding mode and limited specific interactions suggest it is not a promising lead for direct small-molecule drug design.
- Further research may focus on alternative strategies for developing VEGF-targeted cancer therapies.